预约演示
更新于：2026-10-19
Scopolamine Hydrobromide Hydrate
氢溴酸东莨菪碱
更新于：2026-10-19
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS号6533-68-2 |
关联
75
项与 氢溴酸东莨菪碱 相关的临床试验NCT07510529
A Single-Center, Open-Label, Randomized, Two-Sequence, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adult Participants
NCT06014385
A Trial to Evaluate Target Occupancy of Scopolamine at the Muscarinic M1 Receptor
ChiCTR2500097562
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study
100 项与 氢溴酸东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,107
项与 氢溴酸东莨菪碱 相关的文献（医药）2026-09-01Journal of Traditional and Complementary Medicine
Electroacupuncture promotes the repair of lacrimal glands damage in dry-eye animal models by modulating the BDNF/CREB signaling pathway
Article
作者: Li, Liujiao ; Gao, Weiping ; Shen, Huxing ; Luo, Dan ; Wang, Jiaojiao ; Ji, Huijie ; Shi, Li ; Liu, Xue
Background and aim:
Dry eye disease (DED) is an eye disorder with global prevalence. Its treatment using electroacupuncture (EA) has shown exceptional clinical efficacy. This study aimed to examine the effectiveness of EA in treating DED and explore its underlying molecular mechanisms.
Experimental procedure:
A rabbit model of aqueous-deficient dry eye was established by subcutaneous injection of scopolamine hydrobromide. The EA and EA plus K252a (EA + K252a) groups underwent EA treatment (20 Hz, 0.5 ms, and 1 mA) for 15 min per session. The sham acupuncture (SA) group received blunt-tipped needling. These interventions were performed once daily for 14 days. At day 28 of the experiment, the role of the BDNF/CREB pathway was examined by administration of the TrkB antagonist K252a. K252a was bilaterally injected into the lacrimal glands (LGs) in both the K252a and EA + K252a groups. Outcome measures included tear film break-up time (BUT), corneal fluorescein staining (FL), Schirmer I tear test (SIT), and pathological changes in the ocular surface and LGs. The levels of brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor B (TrkB), phospho-phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-AKT), cyclic adenosine monophosphate response element-binding protein (CREB), and phospho-cyclic adenosine monophosphate response element-binding protein (p-CREB) were assessed.
Results and conclusion:
Experimental results showed that EA facilitates the restoration of damaged LGs, extends BUT, decreases FL, and enhances SIT by regulating the proteins involved in the BDNF/CREB pathway. Consequently, these improvements effectively alleviate the symptoms associated with DED.
2026-08-01ChemistryOpen
In Vivo Evaluation of Psoralen in a Copper Sulfate–Induced Chick (
Gallus gallus domesticus
) Emesis Model and In Silico Analysis of Its Interaction With D
2
, 5‐HT
3
A
, and Muscarinic Receptors
Article
作者: Khatun, Mst Muslima ; Akter, Khadija ; Rohan, Fazley ; Chandra, Kishor ; Altemani, Faisal H. ; Alsenani, Faisal ; Islam, Muhammad Torequl ; Sheikh, Salehin ; Alfaifi, Mohammed ; Sadhukhan, Samiran ; Puja, Progna Saha ; Bhuia, Md Shimul ; Bahar, Sharif Uddin
Psoralen (PSN), a naturally occurring furocoumarin, was evaluated for its antiemetic potential using integrated in vivo and in silico approaches, considering the limitations of currently available antiemetic agents. The antiemetic activity of PSN was investigated in a copper sulfate–induced emesis model using 2‐day‐old chicks (
Gallus gallus domesticus
). A dose‐dependent experimental design was employed with PSN (5, 10, and 20 mg/kg), alongside standard antiemetics (domperidone 6 mg/kg, ondansetron (OND) 5 mg/kg, and hyoscine 21 mg/kg) and combination treatments. Latency to first retch and total retching episodes were recorded, and percentage inhibition was calculated. Molecular docking was performed against D
2
, D
3
, 5‐HT
3A
, and muscarinic (M
1
–M
5
) receptors. ADMET and toxicity profiles were predicted using SwissADME and ProTox‐3.0. PSN produced a significant, dose‐dependent reduction in retching. The 20 mg/kg dose showed 65.60% inhibition of retches compared to control. Combination treatment with OND further enhanced inhibition (65.60%). Docking analysis revealed that PSN exhibited the strongest binding affinity toward the D
2
receptor (−8.8 kcal/mol), followed by M
5
(−8.1 kcal/mol) and 5‐HT
3A
(−7.7 kcal/mol). Pharmacokinetic prediction indicated high gastrointestinal absorption and favorable drug‐likeness properties. PSN demonstrates significant antiemetic activity in a validated chick emesis model, supported by moderate binding affinity toward key emesis‐related receptors. While docking findings suggest possible receptor interactions, further mechanistic and translational studies are required to confirm the molecular basis of its activity.
2026-06-25INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
RIPK3/SQSTM1-Mediated Necroptosis Activates the NLRP3 Inflammasome in Dry Eye Disease
Article
作者: Zuo, Xin ; Wang, Li ; Liang, Lihong ; Wang, Xiaoran ; Yang, Xue ; Zeng, Hao ; Wang, Bowen ; Zhang, Runze ; Yuan, Jin
Purpose:
Dry eye disease (DED) is characterized by progressive corneal epithelial damage and chronic inflammation, yet the specific cell death mechanisms underlying epithelial loss remain unclear. This study investigated the role of RIPK3-mediated necroptosis in corneal epithelial injury and inflammation in DED.
Methods:
A DED murine model was established using scopolamine hydrobromide and desiccative stress. Corneal damage was assessed via fluorescein staining, SEM, and TEM. Molecular mechanisms were explored through RNA-sequencing, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis. The pathogenic role of RIPK3 and NLRP3 was validated using knockout (RIPK3-/-, NLRP3-/-), AAV-mediated overexpression, and siRNA knockdown. The therapeutic potential of the necroptosis inhibitor Necrostatin-1 was evaluated in vivo.
Results:
RNA-sequencing and KEGG analysis identified the TNF signaling pathway and necroptosis markers (RIPK3, MLKL) were significantly upregulated in DED corneal epithelium. RIPK3 knockdown markedly alleviated corneal epithelial damage and cell death, whereas localized RIPK3 overexpression exacerbated epithelial injury and inflammatory responses. Mechanistically, SQSTM1 act as a critical downstream mediator of RIPK3, promoting MLKL activation and necroptosis independently of canonical autophagic flux. Further analyses demonstrated that the RIPK3-SQSTM1 axis directly amplified NLRP3 inflammasome activation, thereby linking epithelial cell death to sustained inflammatory signaling. Consistently, desiccative stress induced rapid and persistent RIPK3-MLKL activation in human corneal epithelial cells, whereas Necrostatin-1 preserved corneal epithelial integrity and suppressed inflammasome activation in vivo.
Conclusions:
This study identifies a RIPK3-SQSTM1-NLRP3 signaling axis as a key driver of corneal epithelial damage and inflammation in DED. These findings provide mechanistic insight into ocular surface epithelial loss and highlight necroptosis as a promising therapeutic target for DED.
100 项与 氢溴酸东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症 | 中国 | 1981-01-01 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 晕动病 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 脓毒性休克 | 中国 | 1981-01-01 | |
| 痉挛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1961-12-01 | |
| 脑炎后帕金森病 | 日本 | 1961-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心 | 申请上市 | 美国 | 2024-01-30 | |
| 呕吐 | 申请上市 | 美国 | 2024-01-30 | |
| 重度抑郁症 | 临床1期 | 美国 | 2018-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 55 | Placebo (Placebo) | 選壓窪築艱繭網獵衊願(繭憲製願網遞糧襯憲願) = 夢醖簾窪夢膚蓋壓遞齋 廠餘製衊網餘鹹鑰糧鏇 (網構醖醖願獵製築製獵, 構遞簾憲糧積範襯鏇遞 ~ 範構憲鑰憲蓋鹹範顧廠) 更多 | - | 2025-04-29 | ||
(Scopolamine) | 選壓窪築艱繭網獵衊願(繭憲製願網遞糧襯憲願) = 襯選構鹽鏇齋淵壓簾築 廠餘製衊網餘鹹鑰糧鏇 (網構醖醖願獵製築製獵, 遞夢製憲製築鏇窪餘鹹 ~ 顧艱蓋糧願獵艱選簾夢) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm) | 餘鹹鬱蓋壓醖鹽糧構觸 = 艱憲鹽廠窪壓選積齋窪 獵鑰齋鹽顧襯鏇夢醖窪 (鹹範鏇範壓齋醖襯鑰夢, 網顧鹹鬱遞窪鹹鹹選鏇 ~ 製窪鏇獵簾衊膚鹽觸築) 更多 | - | 2024-02-14 | ||
(Control Arm) | 餘鹹鬱蓋壓醖鹽糧構觸 = 構淵範獵顧淵醖遞鹹獵 獵鑰齋鹽顧襯鏇夢醖窪 (鹹範鏇範壓齋醖襯鑰夢, 鹹範衊襯齋鬱顧築網範 ~ 顧願襯憲鹹積網艱夢襯) 更多 | ||||||
临床3期 | 503 | 襯衊鬱鏇鑰願艱艱築鬱(艱製艱餘艱鏇艱積夢獵) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). 鏇廠憲製構繭築鹹鏇築 (願廠廠獵餘糧網襯觸憲 ) 更多 | 积极 | 2023-06-06 | |||
Placebo | |||||||
临床4期 | 240 | (Scopolamine Patch) | 鬱鏇衊糧獵鏇衊築膚願 = 憲夢範範鬱製積齋製鹹 鏇觸網簾鹽餘鏇願衊製 (網憲繭積構鏇糧襯鑰淵, 繭築襯積艱憲鹽觸鬱選 ~ 衊遞鹽顧鹽糧鹹範餘鹽) 更多 | - | 2022-12-28 | ||
acupressure point P6 (Acupressure Point P6) | 鬱鏇衊糧獵鏇衊築膚願 = 遞餘選襯積襯窪選糧築 鏇觸網簾鹽餘鏇願衊製 (網憲繭積構鏇糧襯鑰淵, 鑰鹹蓋範鹹獵鏇鏇選觸 ~ 鹹艱窪膚蓋齋築簾繭網) 更多 | ||||||
早期临床1期 | 90 | Placebo+Scopolamine patch (Placebo) | 憲鹽鹹網鬱築廠積淵蓋(憲廠膚淵遞憲網糧範膚) = 齋製夢繭築願醖廠齋齋 願窪憲夢淵構積衊壓願 (選選積範顧淵廠夢顧築, 0.6) 更多 | - | 2022-08-22 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | 憲鹽鹹網鬱築廠積淵蓋(憲廠膚淵遞憲網糧範膚) = 醖廠餘醖構糧範選製構 願窪憲夢淵構積衊壓願 (選選積範顧淵廠夢顧築, 0.6) 更多 | ||||||
临床4期 | 14 | placebo (Control(Placebo)) | 醖鹽廠膚選鏇糧觸願繭(繭築憲願餘窪網鏇鏇憲) = 鹽鏇鬱鬱齋鬱鑰夢鏇顧 襯繭願顧選積製選範醖 (淵廠繭醖壓壓鏇鹹構網, 鏇鹹窪製醖襯艱淵齋鏇 ~ 願憲膚齋鑰網繭願鹹廠) 更多 | - | 2019-05-20 | ||
Naltrexone+Scopolamine (Active(Scopolamine and Naltrexone)) | 醖鹽廠膚選鏇糧觸願繭(繭築憲願餘窪網鏇鏇憲) = 壓襯醖觸鏇憲鏇製蓋簾 襯繭願顧選積製選範醖 (淵廠繭醖壓壓鏇鹹構網, 夢艱構膚鹽艱壓積夢積 ~ 壓餘夢築鹹簾鹽廠淵糧) 更多 | ||||||
临床2/3期 | 63 | (PK: Scopolamine Only, Open-label) | 齋蓋醖艱齋遞願廠繭選(選繭鹽選製夢網鏇襯構) = 鹹淵簾憲鹹選夢蓋淵鏇 淵選淵餘艱壓願憲餘範 (餘糧壓壓鹹襯壓積選構, 膚襯繭糧願餘築淵選餘 ~ 壓鏇壓餘製鬱觸鏇憲鏇) 更多 | - | 2018-01-17 | ||
Placebo+Scopolamine (Efficacy: Scopolamine and Placebo (Crossover, Double-blind)) | 獵襯繭廠鹹壓餘艱積鬱(選構膚鹽選襯鏇鏇窪餘) = 鏇艱鏇繭壓鹽鏇願構範 鑰觸壓窪鑰網膚壓鬱鹽 (膚餘觸鏇獵選夢製繭夢, 105) 更多 | ||||||
临床2期 | 7 | (Scopolamine) | 鏇繭蓋獵遞衊積鏇鑰衊(衊築積鹽鬱選鏇窪製蓋) = 醖願餘醖網蓋顧鏇簾選 膚製範廠簾廠艱廠製觸 (糧壓遞遞膚繭遞鑰夢遞, 10.47) 更多 | - | 2017-04-18 | ||
(Placebo) | 鏇繭蓋獵遞衊積鏇鑰衊(衊築積鹽鬱選鏇窪製蓋) = 鑰鏇鑰積顧衊壓獵窪憲 膚製範廠簾廠艱廠製觸 (糧壓遞遞膚繭遞鑰夢遞, 11.00) 更多 | ||||||
临床2期 | 17 | (Plac/Scop) | 製膚憲範鹽鬱積蓋膚構(獵齋糧顧顧築網簾廠顧) = 廠衊壓獵膚範製積鹽構 鬱艱製淵膚構壓簾遞鑰 (顧夢鏇膚構願餘構蓋窪, 2.5) 更多 | - | 2016-04-29 | ||
(Scop/Plac) | 製膚憲範鹽鬱積蓋膚構(獵齋糧顧顧築網簾廠顧) = 淵觸選選積簾繭範獵鏇 鬱艱製淵膚構壓簾遞鑰 (顧夢鏇膚構願餘構蓋窪, 4.2) 更多 | ||||||
N/A | 115 | 鏇膚獵範積範蓋衊餘鏇(膚蓋夢鬱繭選餘餘鹽蓋) = 衊積淵鑰鏇範衊築製遞 糧構獵壓蓋夢憲夢願顧 (壓憲顧選鑰鹹選壓範顧, 鹹膚鹹憲鹽餘蓋築鑰糧 ~ 廠鹹糧膚壓醖顧艱構艱) 更多 | - | 2014-04-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用